Compare Stocks: CCCC, INBX, KLRA, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.16 +10.9%	$3.57	$1.69 ▼ $5.17	$350.62M	3.07	2.19 million shs	2.51 million shs
INBX Inhibrx Biosciences	$95.01 +2.4%	$104.00	$28.16 ▼ $155.29	$1.37B	3.81	258,676 shs	86,818 shs
KLRA Kailera Therapeutics	$11.61 +16.1%	$15.03	$9.76 ▼ $28.23	$1.30B	N/A	1.45 million shs	2.18 million shs
NKTR Nektar Therapeutics	$41.17 +0.9%	$66.54	$33.40 ▼ $109.00	$1.39B	1.26	2.01 million shs	1.17 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+10.88%	+7.12%	-8.14%	-22.17%	+41.70%
INBX Inhibrx Biosciences	+2.43%	-2.04%	-15.82%	+2.15%	+182.68%
KLRA Kailera Therapeutics	+16.10%	+11.74%	-21.77%	-43.86%	+1,160,999,900.00%
NKTR Nektar Therapeutics	+0.91%	-5.53%	-43.85%	-41.49%	-27.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.16 +10.9%	$3.57	$1.69 ▼ $5.17	$350.62M	3.07	2.19 million shs	2.51 million shs
INBX Inhibrx Biosciences	$95.01 +2.4%	$104.00	$28.16 ▼ $155.29	$1.37B	3.81	258,676 shs	86,818 shs
KLRA Kailera Therapeutics	$11.61 +16.1%	$15.03	$9.76 ▼ $28.23	$1.30B	N/A	1.45 million shs	2.18 million shs
NKTR Nektar Therapeutics	$41.17 +0.9%	$66.54	$33.40 ▼ $109.00	$1.39B	1.26	2.01 million shs	1.17 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+10.88%	+7.12%	-8.14%	-22.17%	+41.70%
INBX Inhibrx Biosciences	+2.43%	-2.04%	-15.82%	+2.15%	+182.68%
KLRA Kailera Therapeutics	+16.10%	+11.74%	-21.77%	-43.86%	+1,160,999,900.00%
NKTR Nektar Therapeutics	+0.91%	-5.53%	-43.85%	-41.49%	-27.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.50	Moderate Buy	$8.50	168.99% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	107.87% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	268.22% Upside
NKTR Nektar Therapeutics	2.71	Moderate Buy	$138.50	236.41% Upside

Current Analyst Ratings Breakdown

Latest CCCC, INBX, KLRA, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	CCCC C4 Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
10/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
10/9/2026	NKTR Nektar Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
10/6/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
10/2/2026	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00
9/25/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/18/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/11/2026	INBX Inhibrx Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	10.81	N/A	N/A	$2.65 per share	1.19
INBX Inhibrx Biosciences	$1.30M	1,075.81	N/A	N/A	$0.55 per share	172.75
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	$55.23M	25.45	N/A	N/A	$4.41 per share	9.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)

Latest CCCC, INBX, KLRA, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CCCC C4 Therapeutics	-$0.2010	N/A	N/A	N/A	$8.85 million	N/A
11/5/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.08	N/A	N/A	N/A	$10.31 million	N/A
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.45	5.45
INBX Inhibrx Biosciences	N/A	5.07	5.07
KLRA Kailera Therapeutics	N/A	11.11	11.11
NKTR Nektar Therapeutics	N/A	10.42	10.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
INBX Inhibrx Biosciences	82.46%
KLRA Kailera Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
INBX Inhibrx Biosciences	18.26%
KLRA Kailera Therapeutics	N/A
NKTR Nektar Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
INBX Inhibrx Biosciences	110	14.72 million	12.03 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable

CCCC, INBX, KLRA, and NKTR Headlines

Recent News About These Companies

Raymond James initiates coverage of Nektar Therapeutics with market perform

October 9 at 12:35 AM | msn.com

Nektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from BTIG Research

October 9 at 1:23 PM | marketbeat.com

3 ‘Strong Buy’ High-Risk/High-Reward Stocks to Bank on for 100%+ Upside Potential

October 9 at 12:31 PM | tipranks.com

Raymond James Financial Begins Coverage on Nektar Therapeutics (NASDAQ:NKTR)

October 9 at 8:05 AM | marketbeat.com

Nektar Therapeutics stock faces a cash runway into 2028

October 8 at 2:27 PM | ad-hoc-news.deA

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

October 7 at 1:11 PM | insidermonkey.com

Two Seas Capital LP Grows Stock Position in Nektar Therapeutics $NKTR

October 6, 2026 | marketbeat.com

B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

October 4, 2026 | theglobeandmail.com

Nektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from HC Wainwright

October 4, 2026 | americanbankingnews.com

Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow

October 3, 2026 | seekingalpha.com

Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More

October 2, 2026 | seekingalpha.com

Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.7% - Should You Sell?

October 2, 2026 | marketbeat.com

Nektar Therapeutics' (NKTR) Buy Rating Reaffirmed at HC Wainwright

October 2, 2026 | marketbeat.com

Nektar Therapeutics tumbles despite long-term benefit from alopecia drug

October 2, 2026 | msn.com

Transcript : Nektar Therapeutics - Shareholder/Analyst Call

October 2, 2026 | marketscreener.comM

Nektar Reports Durable Rezpegaldesleukin Data In Alopecia Areata And Atopic Dermatitis

October 2, 2026 | rttnews.com

Nektar drops after new mid-stage trial data for hair loss drug

October 2, 2026 | seekingalpha.com

Nektar posted promising alopecia results. Here's why it took a 20%-plus hit.

October 2, 2026 | msn.com

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

October 1, 2026 | seekingalpha.com

Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down - What's Next?

October 1, 2026 | marketbeat.com

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial

October 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CCCC, INBX, KLRA, and NKTR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$3.16 +0.31 (+10.88%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.15 -0.01 (-0.25%)

As of 10/9/2026 07:59 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Inhibrx Biosciences NASDAQ:INBX

$95.01 +2.25 (+2.43%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$95.10 +0.09 (+0.10%)

As of 10/9/2026 07:30 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Kailera Therapeutics NASDAQ:KLRA

$11.61 +1.61 (+16.10%)

As of 10/9/2026 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Nektar Therapeutics NASDAQ:NKTR

$41.17 +0.37 (+0.91%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.91 -0.26 (-0.64%)

As of 10/9/2026 07:30 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, INBX, KLRA, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, INBX, KLRA, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, INBX, KLRA, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CCCC, INBX, KLRA, and NKTR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Inhibrx Biosciences NASDAQ:INBX

Kailera Therapeutics NASDAQ:KLRA

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, INBX, KLRA, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, INBX, KLRA, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, INBX, KLRA, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CCCC, INBX, KLRA, and NKTR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Inhibrx Biosciences NASDAQ:INBX

Kailera Therapeutics NASDAQ:KLRA

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools